How the Loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance

NCT00040196 | Completed

• 2 other identifiers: 02021602-N-0216
• Study Type: observational
• Target: 133
• Locations: 1 country
• Sites: 1

Brief Summary

This study has two purposes: 1) to understand the effect of a decline of dopamine in the brain during normal aging and in patients with Parkinson's disease, and 2) to investigate how medicines used to treat Parkinson's disease improve movement performance in patients. Patients with Parkinson's disease have difficulty performing precise finger movements, mainly because of a dramatic decrease of a substance called dopamine in parts of the brain. Medicines such as levodopa, which help restore dopamine levels, can greatly improve function; however, little is known about how these drugs work. In normal aging, dopamine decreases slightly in certain parts of the brain, but the importance of this decline is poorly understood. This study may provide new information about Parkinson's disease and normal aging that might lead to better treatment strategies. Patients with mild to moderate Parkinson's disease and healthy volunteers 21 years of age and older may be eligible for this study. All participants must be right-handed. All candidates will be screened with a medical history and physical and neurological examinations, including memory tests and mood examination. Brain function will be studied using functional magnetic resonance imaging (fMRI) study and positron emission tomography (PET). Participants may be asked to stop using medications that can affect the central nervous system, such as sleeping pills or drugs for depression or anxiety, for 1 week before each study visit. Patients with Parkinson's disease may also be asked to stop using antiparkinsonian medications at least 12 hours before each visit. In addition, all participants will be asked to abstain from alcoholic beverages at least 24 hours before the fMRI and PET scans, and from nicotine and caffeine for at least 12 hours before the scans. Participants will have fMRI, which uses a strong magnetic field and radio waves to create images of the brain. The subject lies on a table in a tunnel-like cylinder (the scanner) for 1 to 2 hours, lying still for 5 to 15 minutes at a time. He or she can communicate with the technician or researcher at all times during the test through an intercom system. Scans will be done while the subject is at rest and while he or she is performing finger movements. The movements involve pushing five buttons on a box-each button every 3 seconds on average in a specific order. Patients with Parkinson's disease will be studied off- and then on- medications that restore the levels of levodopa in the brain. Some participants may be asked to undergo a PET scan on a separate visit. A PET scanner is a doughnut-shaped machine similar in appearance to a CT (computed tomography) scanner. PET scans detect radioactivity used to provide information on brain activity. Before the test begins, subjects are given a dose of carbidopa-a medicine that increases the amount of levodopa in the brain. A catheter (thin, plastic tube) is then inserted into an arm or wrist vein, and a radioactive form of levodopa called 18Fluorodopa is injected through the catheter. A moldable plastic mask with large openings for eyes, nose, and mouth is placed on the face to help keep the head still during scanning. The total scan time is 2 hours or less.

Conditions

Parkinson Disease

Keywords

Parkinson's Disease; Levodopa; Perfusion fMRI; Aging; Motor Control; PD; Healthy Volunteer; HV; Normal Control

Eligibility Criteria

• Age: 21 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• We will only include PD patients with a stable clinical response to L-DOPA and DAergic agents.
• We will only recruit patients with early or mild-to-moderate PD (score on Hoehn \& Yahr scale 148 less than 3).
• To obtain a homogeneous group, the PD cohort will comprise only non-demented, non-depressed, with parkinsonian symptoms and signs primarily akineto-rigid.
• If resting tremor is present, only patients with mild or moderate tremor (UPDRS tremor ratings 1 or 2 in the right upper limb) will be included in the study.
• Our group of healthy volunteers will include the following age range: 21-30 years, 31-40 years, 41-50 years, 51-60 years, 61-70 years, and 70 years and over.
• Research subjects may be male or female and they must be right-handed.
• Pregnant women will not participate in the study.
• Research subjects will be asked to refrain from caffeine and nicotine for at least 12 hours and to abstain from alcohol at least 24 hours before the fMRI.

You may not qualify if:

• Subjects belonging to one of the following groups will be excluded from the study:
• Subjects with a familial history of PD.
• Patients with a marked resting tremor (score at the UPDRS scale above 3 in the right upper limb).
• Patients with a score at Hoehn \& Yahr scale equal or above 3.
• Patients with progressive neurological disorders other than PD.
• Subjects with cognitive impairment (i.e., score on Mattis scale below 123/144).
• Subjects with significant mood disturbances (i.e., score on BDI scale above 10).
• Subjects with abnormal MRI findings at visual inspection (prominent normal variants such as mega cisterna or cavum septum pellucidum, signs of severe cortical or subcortical atrophy, brain tumors, vascular diseases, trauma or AVMs).
• Subjects with a history of significant medical disorders, or requiring chronic treatment with other drugs that cannot be stopped.
• Subjects with prior exposure to neuroleptic agents or drug use.
• Subjects with significant past and present history of hypertension, cardiovascular disease and diabetes mellitus.
• Subjects with severe orthopedic or rheumatologic pathology of the right upper limb.
• Subjects with past or present neuropsychiatric illness, head trauma with loss of consciousness, epilepsy, cerebro-vascular disease, past and present history of alcohol or substance abuse, including cigarettes, medical conditions that may alter cerebral functioning
• Subjects with cancer.
• Subjects who have pacemakers, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including heart valves and cochlear implants) or shrapnel fragments.

Sponsors & Collaborators

• National Institute of Neurological Disorders and Stroke (NINDS): lead

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

• Kupfermann I. Modulatory actions of neurotransmitters. Annu Rev Neurosci. 1979;2:447-65. doi: 10.1146/annurev.ne.02.030179.002311.

  PMID: 44174 BACKGROUND

• Melamed E, Lavy S, Cooper G, Bentin S. Regional cerebral blood flow in parkinsonism. Measurement before and after levodopa. J Neurol Sci. 1978 Oct;38(3):391-7. doi: 10.1016/0022-510x(78)90144-2.

  PMID: 731264 BACKGROUND

• Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Langstrom B. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Neurology. 1996 May;46(5):1430-6. doi: 10.1212/wnl.46.5.1430.

  PMID: 8628494 BACKGROUND

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Design

• Study Type: observational
• Sponsor Type: NIH

Study Record Dates

• First Submitted: June 21, 2002
• First Posted: June 24, 2002
• Study Start: June 19, 2002
• Primary Completion: July 9, 2009
• Study Completion: July 9, 2009
• Last Updated: July 2, 2017

Record last verified: 2009-07-09

Locations

US (1)